Skip To Main Content
Olayinka Osoba on Muck Rack

Olayinka Osoba

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Olayinka

Contact Olayinka, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-World 12 and 18-Month Outcomes of Faricimab in Patients Previously Treated for Neovascular Age-Related Macular Degeneration

|
By Tun Giap Tan, Radua Kamal-Salah, Olayinka Osoba
| preprints.org
You are already at the latest version Age-related macular degeneration (nAMD) is a significant cause of visual impairment globally.1 This single-centre retrospective study evaluated real-world outcomes of faricimab in patients with neovascular age-related macular degeneration (nAMD) who responded suboptimally to other anti-VEGF treatment. Patients with nAMD who were switched to faricimab between September and December 2022 with a minimum of 12 months’ follow-up were included.
Open in Who Shared Issue with article?
See all 1 articles